The primary goal of this study is to determine if the addition of the bladder antispasmotic
oxybutynin to standard antimicrobial therapy in the treatment of childhood cystitis will
decrease the associated pain and discomfort. A randomized, double blind, placebo-controlled
clinical trial design will be used. The second goal of this study will be to describe the
nature and duration of symptoms associated with uncomplicated cystitis in the paediatric age
group. Finally, adverse side effects associated with short term use of oxybutynin will be
monitored.